Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
Stopped Unfavorable benefit-risk balance in the experimental arm following the IDMC for intermediate efficacy and safety analysis
Conditions
- Adenocarcinoma of the Stomach
- Adenocarcinoma of the Gastroesophageal Junction
Interventions
- COMBINATION_PRODUCT: Regorafenib and Irinotecan
- DRUG: Irinotecan
Sponsor
UNICANCER
Collaborators